Tumor TARGET Prostate Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by University Health Network, Toronto
Sponsor:
Collaborator:
Princess Margaret Hospital, Canada
Information provided by (Responsible Party):
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT01802242
First received: October 22, 2012
Last updated: June 24, 2014
Last verified: June 2014
  Purpose

Prostate cancer is common in males and may develop over the course of an individual's life. This cancer is often discovered at the time of routine physical examinations and/or blood work or on rectal examination. Once diagnosed, most patients do require some form of treatment so that the prostate cancer does not progress to cause damage and/or shortened lifespan. Occasionally, after patients receive treatment, the investigators have found that an area of cancer remains within the prostate. Those patients with a large area of cancer (i.e. seen on MRI image) appear to have a higher chance of remaining or recurrent prostate cancer even after standard treatment. Thus, the investigators believe that the area of the prostate gland occupied by a dense area of cancer may need more radiation therapy than normal to remain cancer free.

Standard therapy currently in place in North America: Currently patients who are diagnosed with prostate cancer have 3 common options: surgery, external beam radiation therapy (EBRT) alone or internal radiation (brachytherapy). Patients may or may not receive hormone therapy alongside the radiation depending on their physician's preference. For those who receive radiation therapy, the tumor typically receives the same dose as the rest of the prostate gland.

Findings to date: In the past few years the investigators have discovered that patients with a tumor large enough to be seen on MRI images (>5mm) have a higher chance than normal of having cancer remain in the prostate, despite receiving treatment for their cancer 3 years earlier. Using new technology investigators can deliver radiation therapy after viewing the prostate tumor on MRI. This guides therapy, allowing the radiation treatment to be targeted to the tumor within the prostate. Based on this earlier success the investigators believe that they can now safely give a higher dose of radiation to specifically target the cancer within the prostate gland.

Reason for the study: The investigators would like to test this technology and expertise to give radiation to a higher than normal dose to the tumor nodule in prostate gland.


Condition Intervention Phase
Patients With Prostate Cancer.
Radiation: Volumetric Modulated Arc Therapy (VMAT) and High-Dose Rate (HDR) Radiotherapy
Other: No Active Treatment - completed Prior Radiation
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Tumor Targeted Radiotherapy for Patients With Localized Prostate Cancer

Resource links provided by NLM:


Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures:
  • Determine rates of Local Control after standard targeted boost radiotherapy in patients with localized prostate cancer. [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Determine if high‐dose tumor‐targeted radiotherapy for localized prostate cancer can be integrated in a standard‐care workflow. [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • Determine a methodology with appropriate uncertainty margins for Gross Tumour Volume boost [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Evaluate the spatial distribution of prostatic carcinoma at the time of repeat biopsy [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Compare dose to recurrent and non‐recurrent tumor nodules. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Determine rates of toxicity with tumor‐targeted boost radiotherapy. [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • Assess Quality of Life (QoL) outcomes after high‐dose tumor‐targeted boost therapy. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Determine patient acceptance of combination of high dose rate and volumetric modulated arc therapy techniques [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Determine clinical outcomes by comparing integrated boost volumetric modulated arc therapy and a combination of high dose rate and volumetric modulated arc therapy techniques. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Determine dosimetric outcomes by comparing integrated boost volumetric modulated arc therapy and a combination of high dose rate and volumetric modulated arc therapy techniques. [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • Explore the predictive value of baseline and early response imaging biomarkers on Local Control. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Bank tissue and biofluids for future exploration of the relationship between biopsy tissue/serum/urine and disease recurrence. [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 110
Study Start Date: October 2012
Estimated Study Completion Date: October 2015
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Active Radiation Treatment (Cohort 2) Radiation: Volumetric Modulated Arc Therapy (VMAT) and High-Dose Rate (HDR) Radiotherapy

Patients in this group will receive one of 2 treatment arms of their choice:

  • Arm 1: VMAT delivery with integrated VMAT boost (IB‐VMAT) GTV: 95Gy in 38fractions
  • Arm 2: HDR‐boost followed by VMAT GTV: 10Gy HDR + 76Gy in 38 fractions VMAT
Prior Radiation Treatment (Control Cohort)
Patients who received 78Gy RT to the prostate gland 3‐4.5 years prior to enrollment. This group will not be receiving any active treatment
Other: No Active Treatment - completed Prior Radiation
Already had prior radiation treatment. MRI‐guided prostate biopsy at 3 years and PSA per standard practice

Detailed Description:

This is a prospective two arm phase 2 trial investigating the technical and clinical performance of tumor-targeted (rather than prostate targeted) radiotherapy.

Cohort 1 (Control group): This group consists of patients who have had previous radiation. This group will not receive any active treatment but will have a biopsy at 3 years from the time they completed their radiation therapy. Patient in this group will also continue to have their PSA checked per standard practice

Cohort 2 (Experimental group): Patients in this group will receive one of 2 treatment arms of their choice. In addition to the MRI-guided prostate biopsy at 3 years and regular standard of care PSA checks, this group will also complete a quality of life questionnaire and have regular imaging per standard practice.

Both groups will be followed by the research team per protocol.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria [applicable to both Cohorts 1 (control) and Cohort 2 (Experimental) unless otherwise specified]:

  1. Histological evidence of prostate adenocarcinoma.
  2. Discrete intra‐prostatic tumor that can be confidently visualized on MRI prior to radiotherapy (>5mm maximum diameter but <33% of prostate volume, biopsy confirmed)
  3. At least 18 years old
  4. ECOG performance status 0 or 1 with > 10‐year life expectancy
  5. Informed consent: All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed (this does not include standard care laboratory tests or imaging studies).
  6. Patients will be one of the following risk groups prior to therapy:

    • Low‐risk disease (Gleason 6 and PSA <10 and T1) AND >50% of biopsy cores involved with tumor
    • Intermediate‐risk disease (Gleason 7 or PSA 10‐20 or T2)
    • High‐risk disease (Gleason >8 or T3 or PSA >20)
  7. Risk of LN involvement <30% (Roach formula = 2/3PSA([G‐6]x10))
  8. Patients who received 78Gy RT to the prostate gland 3‐4.5 years prior to enrollment (Cohort 1 only)

Exclusion Criteria [applicable to both Cohorts 1 (control) and Cohort 2(Experimental) unless otherwise specified]:

  1. Previous history of radiation therapy to the prostate (Cohort 2)
  2. Diagnosis of another cancer not being skin cancer within the last 5 years (Cohort 2)
  3. Patients weighing >136kgs (weight limit for the scanner tables)
  4. Patients with contraindications to MRI: this includes patients with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic devices not compatible with MRI determination. Exceptions will be allowed if deemed sage and appropriate by the MRI technologist.
  5. Severe claustrophobia
  6. Bleeding diathesis and anti‐coagulative therapy that cannot be temporarily ceased precluding biopsy
  7. Current hormonal therapy (Cohort 1) or initiated >2 weeks prior to enrollment (Cohort 2)
  8. Radiological evidence of regional or distant metastases (Cohort 2)
  9. Other urinary or medical conditions deemed by the PI or associates to make the patient ineligible for MRI‐guided prostate biopsy
  10. Contraindications to the endorectal coil, surgically absent rectum, severe hemorrhoids or previous colorectal surgery
  11. Contraindications to conscious sedation
  12. Latex allergy
  13. History of Ulcerative Colitis, Crohn's Disease, Ataxia Telangiectasia, or SLE (Cohort 2)
  14. Other medical conditions deemed by the PI to make patient ineligible for study intervention
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01802242

Contacts
Contact: Cynthia Ménard, MD 416 946 4501 ext 2919 cynthia.menard@rmp.uhn.on.ca
Contact: Peter Chung, MB ChB 416 946 4501 ext 6522 Peter.Chung@rmp.uhn.on.ca

Locations
Canada, Ontario
University Health Network, The Princess Margaret Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Cynthia Ménard, MD    416 946 4501 ext 2919    cynthia.menard@rmp.uhn.on.ca   
Contact: Peter Chung, MB ChB    416 946 4501 ext 6522    Peter.chung@rmp.uhn.on.ca   
Principal Investigator: Cynthia Ménard, MD         
Sponsors and Collaborators
University Health Network, Toronto
Princess Margaret Hospital, Canada
Investigators
Principal Investigator: Cynthia Ménard, MD University Health Network, The Princess Margaret
  More Information

No publications provided

Responsible Party: University Health Network, Toronto
ClinicalTrials.gov Identifier: NCT01802242     History of Changes
Other Study ID Numbers: UHN REB 12-5015-C
Study First Received: October 22, 2012
Last Updated: June 24, 2014
Health Authority: Canada: Ethics Review Committee

Keywords provided by University Health Network, Toronto:
Prostate Cancer
Prostate tumour
Prostate radiotherapy
prostate cancer treatment

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on September 18, 2014